On this page
1How to use this
These are open treatment trials from ClinicalTrials.gov whose records suggest a patient with myoepithelial carcinoma might be eligible1. 89 open trials were read. The ones limited to other tumor types are left out.
This is a list of questions, not of places. Eligibility was judged by a model from
the first part of each record's criteria and has not been checked by a clinician or with the trial. Only the trial
team can say whether a particular patient qualifies. Status changes: check the registry link.
2Trials that name the disease
| Registry ID | Trial | Phase | Status | Where | Treatment | Why it is listed |
|---|---|---|---|---|---|---|
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | Phase 1, Phase 2 | Recruiting | United States | alpha/beta T and B cell depleted haplo-identical transplant with zoledronic acid | Lists 'myoepithelial tumor' among eligible high-risk extracranial solid tumors; ages 6 months to 25 years, donor needed. Tumor, not specifically carcinoma. |
3Open to any advanced or rare solid tumor
| Registry ID | Trial | Phase | Status | Where | Treatment | Why it is listed |
|---|---|---|---|---|---|---|
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Phase 1 | Recruiting | United States | MQ710 oncolytic virus with or without pembrolizumab | Advanced relapsed cancer with injectable lesions; mostly skin cancers named, any malignancy with superficial lesions may qualify at investigator discretion. |
| NCT05941507 | A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Phase 1, Phase 2 | Recruiting | Canada, United States | LCB84 (TROP2 antibody-drug conjugate) with or without anti-PD-1 | Phase 1: advanced solid tumors; phase 2 expansion limited to select tumors to be chosen later. |
| NCT06647342 | The Effect of Reduced Bleomycin in Electrochemotherapy Treatment | Phase 4 | Recruiting | Denmark | electrochemotherapy with reduced-dose bleomycin | Skin or subcutaneous primary or secondary cancer 'of any histology'; treats skin lesions only. |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Phase 1, Phase 2 | Active not recruiting | Australia, United States | ONC-392 alone or with pembrolizumab | Part A: advanced/metastatic solid tumors of any histology; later parts limited to listed tumor types. |
4Salivary gland cancers, including the rarer types
| Registry ID | Trial | Phase | Status | Where | Treatment | Why it is listed |
|---|---|---|---|---|---|---|
| NCT05000892 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | Phase 2 | Recruiting | China | neoadjuvant sintilimab, carboplatin, nab-paclitaxel | Salivary gland cancers: several named types 'or other histology'. |
| NCT06421649 | Investigating the Role of Adjuvant Proton Beam Therapy in Patients With Parotid Carcinoma | NA | Recruiting | United Kingdom | adjuvant proton beam therapy | Histologically confirmed primary malignant tumours of parotid gland, no histology limit. |
| NCT06805617 | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers | Phase 2 | Recruiting | United States | ivonescimab | Salivary gland carcinoma 'any histologic subtype, including ACC'. |
| NCT02998385 | Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) | Phase 3 | Active not recruiting | France | chemoradiotherapy with cisplatin versus radiotherapy | Salivary gland or sinus carcinomas of 'any histological type' except melanoma, lymphoma, sarcoma, squamous, nasopharyngeal. |
| NCT03360890 | Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors | Phase 2 | Active not recruiting | United States | pembrolizumab with docetaxel | Cohort A salivary gland cancers listing several types 'or other histology'. |
| NCT04209660 | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | Phase 2 | Active not recruiting | United States | lenvatinib and pembrolizumab | Cohort 2: salivary gland cancer of any histology except adenoid cystic. |
| NCT04825938 | Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | Phase 2 | Not yet recruiting | China | neoadjuvant toripalimab, carboplatin, nab-paclitaxel | Salivary gland cancers: several named types 'or other histology'. |
| NCT05010629 | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | Phase 2 | Active not recruiting | United States | 9-ING-41 with carboplatin | Salivary gland carcinoma 'any histologic subtype, including ACC'. |
| NCT07928193 | Sac-TMT in Salivary Gland Cancers | Phase 2 | Not yet recruiting | Brazil | sacituzumab tirumotecan (Sac-TMT) | Cohort 2: non-adenoid cystic carcinoma of the salivary gland. |
5Salivary gland cancers, where the record does not say which types
| Registry ID | Trial | Phase | Status | Where | Treatment | Why it is listed |
|---|---|---|---|---|---|---|
| NCT06923826 | Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) | Phase 2 | Recruiting | Singapore | sacituzumab govitecan | Advanced salivary gland cancer (or thyroid); no histology list given; age 21 or older. |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | Phase 1, Phase 2 | Recruiting | United States | docetaxel with SX-682 | Title lists head and neck squamous, salivary gland carcinoma and prostate cancer; salivary histology criteria not visible in the cut-off text. |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Phase 2 | Active not recruiting | pembrolizumab | Lists 'Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)' with no histology limits; other cohorts MSI-H/TMB-H. | |
| NCT03781986 | APG-115 in Salivary Gland Cancer Trial | Phase 1, Phase 2 | Active not recruiting | United States | APG-115 (MDM2 inhibitor) with carboplatin | Malignant salivary gland cancers generally, but histologies not spelled out; needs no p53 mutation. Needs: no TP53 mutation. |
| NCT04895735 | MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | Phase 2 | Active not recruiting | United States | pemetrexed and pembrolizumab | Recurrent or metastatic salivary gland cancer; one cohort is ACC but other histologies not spelled out. |
| NCT05075980 | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study | Phase 2 | Active not recruiting | United States | proton versus X-ray radiation with cisplatin | Non-HPV 'malignant epithelial cancer' of head and neck including salivary primary; histology not clearly defined. |
| NCT05608876 | A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer | Phase 2 | Active not recruiting | Australia, United Kingdom | intratumoural tigilanol tiglate | Head and neck tumour types 'can include' squamous, sino-nasal, salivary gland cancers; histologies not specified. |
| NCT05884320 | Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers | Phase 2 | Active not recruiting | United States | sacituzumab govitecan | Histology-proven R/M salivary gland cancer; Cohort 1 is ACC, other cohort details cut off. |
| NCT05924256 | A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing | Phase 2 | Active not recruiting | China | SHR-A1811, SHR-3680 with leuprolide, SHR-A1921 | Salivary gland carcinoma assigned to arms by molecular typing; Arm 3 lacks HER2 alteration and AR, histologies not specified. Needs: arms by HER2 overexpression, AR positive, HER2-low; one arm has neither. |
6Soft-tissue sarcoma, broadly
| Registry ID | Trial | Phase | Status | Where | Treatment | Why it is listed |
|---|---|---|---|---|---|---|
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | Phase 1, Phase 2 | Recruiting | United States | pazopanib, ifosfamide/doxorubicin, selinexor, proton radiation, surgery | Ages 1-30, non-rhabdomyosarcoma soft tissue sarcoma; myoepithelial flag is true but wording not visible in the shown text, so cautious. |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | Phase 2 | Recruiting | China | ivonescimab | Lists 'other sarcoma' besides rhabdomyosarcoma, plus several rare tumors; myoepithelial not named. |
7Open only to tumors with a named marker
| Registry ID | Trial | Phase | Status | Where | Treatment | Why it is listed |
|---|---|---|---|---|---|---|
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Phase 1, Phase 2 | Recruiting | Puerto Rico, United States | VMD-928 (TrkA inhibitor), with pembrolizumab | Phase 2 needs TrkA-driven head and neck/other cancers or NTRK1-positive tumors. Needs: TrkA overexpression or NTRK1 fusion. |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Phase 1 | Recruiting | United States | oncolytic adenovirus with HER2-specific CAR virus-specific T cells | Basket for HER2-positive solid tumors, including salivary gland; HER2 IHC 2+ needed. Needs: HER2 positive by IHC (2+ or more). |
| NCT04620187 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | Phase 2 | Recruiting | United States | T-DM1 with radiotherapy/chemotherapy | Salivary carcinoma of any histologic subtype but must be HER2 positive. Needs: HER2 positive (IHC 2-3+, amplification or mutation). |
| NCT05408845 | Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | Recruiting | United States | ado-trastuzumab emtansine versus docetaxel/trastuzumab or trastuzumab deruxtecan | Requires HER2-positive or HER2-low salivary gland cancer by IHC, FISH or NGS. Needs: HER2-positive or HER2-low expression. |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations | Phase 2, Phase 3 | Recruiting | United Kingdom | trastuzumab with pertuzumab | Needs malignancy harbouring HER2 amplification or activating mutation; age 12 and over. Needs: HER2 amplification or activating mutation. |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | Phase 2 | Recruiting | China | HER2 ADC, NTRK TKI, androgen blockade, TROP2 ADC | Salivary gland carcinoma stained for HER2/NTRK/AR/TROP-2 with marker-matched cohorts; fully biomarker-guided. Needs: HER2, NTRK fusion/mutation, AR or TROP2 by IHC. |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Recruiting | Georgia, South Korea, Spain, United States | zanidatamab | HER2 overexpression IHC 3+ required; biliary tract cancer excluded. Needs: HER2 overexpression (IHC 3+) by central lab. |
| NCT06760819 | A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 2 | Recruiting | Australia, Canada, China, Denmark and others | sevabertinib (BAY 2927088) | Solid tumors with documented activating HER2 mutation; NSCLC excluded. Needs: documented activating HER2 mutation. |
| NCT07464366 | The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study | Phase 2 | Recruiting | China | MRG003 (EGFR ADC) with or without pucotenlimab | Salivary gland cancer incl. several major subtypes, but needs immunohistochemically confirmed EGFR expression. Needs: EGFR expression by IHC. |
| NCT07815522 | Abiraterone With Dalpiciclib in Salivary Gland Carcinoma | Phase 2 | Recruiting | China | abiraterone with dalpiciclib | Salivary gland malignancy that is HER-2-negative and AR-positive by IHC. Needs: AR positive and HER2 negative by IHC. |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Phase 2 | Active not recruiting | Australia, Belgium, China, France and others | entrectinib | Solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement. Needs: NTRK1/2/3, ROS1 or ALK gene rearrangement. |
| NCT02650401 | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | Phase 1, Phase 2 | Active not recruiting | Canada, China, France, Germany and others | entrectinib | Current parts require extracranial solid tumors with NTRK1/2/3 or ROS1 fusions. Needs: NTRK1/2/3 or ROS1 gene fusion. |
| NCT02749903 | Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers | Phase 2 | Active not recruiting | United States | enzalutamide | Salivary cancer with AR expression detected by immunohistochemistry on central review. Needs: androgen receptor expression by IHC. |
| NCT03942653 | Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | Phase 2 | Active not recruiting | United States | goserelin and pembrolizumab | Needs AR-positive salivary gland carcinoma confirmed centrally. Needs: androgen receptor positive (at least 20% IHC). |
| NCT04325828 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma | Phase 2 | Active not recruiting | Japan | apalutamide with GnRH agonist | Salivary gland carcinoma that is AR expressing by IHC. Needs: androgen receptor positive (at least 1% nuclei by IHC). |
| NCT04639219 | A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations | Phase 2 | Active not recruiting | Belgium, Canada, Denmark, France and others | trastuzumab deruxtecan | Solid tumors with listed HER2 mutations on tumor sequencing. Needs: pre-specified HER2 activating mutations. |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Phase 1 | Active not recruiting | United States | trastuzumab deruxtecan with ceralasertib | Patients must have HER2-positive or HER2-expressing tumors. Needs: HER2 expression (IHC 1-3+) or amplification. |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Phase 1 | Active not recruiting | United Kingdom, United States | AVA6000 (FAP-activated doxorubicin) | Phase 1a tumours reported FAP positive; salivary carcinoma or soft tissue sarcoma; phase 1b limited to DDLS/UPS, SGC, TNBC. Needs: FAP positive tumor (phase 1a). |
| NCT05669664 | Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers | Phase 2 | Active not recruiting | United States | darolutamide with leuprolide | Salivary gland cancer with AR expression detected by IHC. Needs: androgen receptor expression by IHC. |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors | Phase 2 | Active not recruiting | Brazil | nivolumab | Rare cancer on a listed set (others by study board approval) and PD-L1 CPS >= 10; myoepithelial not named. Needs: PD-L1 combined positive score 10 or higher. |
8What to ask
- Does this trial accept myoepithelial carcinoma, and has it enrolled anyone with it?
- Does my tumor need a particular marker or fusion to qualify, and has mine been tested?
- Which sites are open, and what would taking part involve?
What has already been tried is on the treatments page.